. . . . . . . . . . . . "[Vasoactive intestinal peptide (VIP) has been considered as a promising drug candidate for asthma and COPD because of its potent immunomodulating and anti-inflammatory activities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2016-01-25"^^ . . "Gene-disease associations inferred from animal model manually asserted gene-disease associations."@en . "DisGeNET evidence - PREDICTED"@en . "2016-05-13T12:42:17+02:00"^^ . . . . . . . . . . . "v4.0.0.0" . "v4.0.0" .